We therefore hypothesized that the unique sensitivity to ABT-263 seen in MYCN-amplified cells would be preserved following ABT-199 treatment; in fact, we found that MYCN-amplified neuroblastoma cells remained sensitive to ABT-199, while MYCN-WT neuroblastoma cells and RPE-1 cells were insensitive to ABT-199, consistent with their insensitivity to ABT-263 (Figures 3B and S3A). The gene discussed is MYCN; the disease is neuroblastoma.